Ojjaara (Momelotinib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending
Ojjaara (Momelotinib Dihydrochloride) by GSK: FDA Orange Book core substance LOE 2035-06-11 (last listed 2040-12-02), 0 AB generics, $351.7M 2024 CMS Part D & Medicaid spend, and $26,900 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N216873 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-06-11 |
| Last Listed Patent or Exclusivity Date | 2040-12-02 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $351.7M |
| 2024 Medicare Part D Spend | $341.7M |
| 2024 Medicaid Spend | $10.0M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($26,900 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.